A Phase 2 interventional study of Oral Budesonide Suspension (MB-9) and Placebo in Eosinophilic Esophagitis (EoE), sponsored by Shire. Completed at 23 sites in United States. Open to participants aged 11 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-06-08.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing budesonide in Eosinophilic Esophagitis — 1 open to participants now, 2 under way, 1 of them phase 3. Budesonide · Eosinophilic Esophagitis.
Among the 18 studies testing budesonide in Eosinophilic Esophagitis, this one is the 7th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 2, and was the 5th registered.
235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.
Browse Eosinophilic Esophagitis studies →1 of the 18 studies testing budesonide in Eosinophilic Esophagitis is open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.
This study: 11 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 7 · Phase 4 3
First in 2005; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 93 is above the median of 42 across 134 interventional studies indexed under Eosinophilic Esophagitis.
Median enrollment 79 across the 18 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
Takeda has 5 studies filed under Eosinophilic Esophagitis — fewer than ten, so there is no comparison to draw.
1 of the studies testing budesonide in Eosinophilic Esophagitis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06596252Phase 3Dr. Falk Pharma GmbHOnce Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing budesonide in Eosinophilic Esophagitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a clinical trial to test an experimental drug for the treatment of Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis (EoE) is an inflammatory disorder of the esophagus and is a recognized clinical entity. Symptoms include feeding problems, heartburn, regurgitation, vomiting, abdominal pain and food impaction. The symptoms of EoE may be similar to gastroesophageal reflux disease (GERD) but do not resolve with gastric acid suppression. EoE is defined histologically as the presence of > 15 intraepithelial eosinophils per high power fields on one or more esophageal biopsy specimens.
This Phase II study is comparing oral budesonide (OBS) to placebo to demonstrate that OBS induces a histologic response and a symptom response using a Dysphagia Symptom Questionnaire over a 16 week course of therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Taken once or twice daily for up to 40 weeks
Drug: Oral Budesonide Suspension (MB-9)
Taken once or twice daily for 20 weeks
Drug: Placebo
OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period
Percent of Participants Who Were Histologic Responders
Histologic response was defined as a peak eosinophil count \</= 6/high power field (light microscopy) (HPF) across all esophageal levels at the final treatment evaluation (Week 16). An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value. Histopathology data were collected in a blinded fashion.
Time frame: Week 16
Change From Baseline in The Dysphagia Symptom Questionnaire (DSQ) Score at The Final Treatment Period Evaluation
Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing).The DSQ score was calculated based on responses to Questions 2 and 3 \[14 x (sum of points from Questions 2 and 3 in the daily DSQ)/number of diaries with non-missing data\]. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.
Time frame: Baseline, Week 16
Change From Baseline in The DSQ Score Over Time
Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing).The DSQ score was calculated based on responses to Questions 2 and 3 \[14 x (sum of points from Questions 2 and 3 in the daily DSQ)/number of diaries with non-missing data\]. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.
Time frame: Baseline, Weeks 8 and 12
Change From Baseline in The DSQ Score For The 50th Percentile of Participants at The Final Treatment Period Evaluation
A cumulative distribution function curve was constructed to illustrate the cumulative proportion of participants (x-axis) vs. the change in the DSQ score from baseline to the final treatment evaluation (y-axis). The 50th percentile is participants with a DSQ score that is in the middle of the distribution of all scores. A negative change from baseline indicates that symptoms decreased.
Time frame: Baseline, Week 16
Percent of Participants With a Peak Eosinophil Count </= 15/High Power Field (Light Microscopy) (HPF) And </= 1/HPF at The Final Treatment Period Evaluation
An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value across all available esophagus levels. Histopathology data were collected in a blinded fashion. The values reported are for participants with histologic response.
Time frame: Week 16
Percent of Participants With a >/= 30% And >/= 50% Reduction In The DSQ Score From Baseline to The Final Treatment Period Evaluation
Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing).The DSQ score was calculated based on responses to Questions 2 and 3 \[14 x (sum of points from Questions 2 and 3 in the daily DSQ)/number of diaries with non-missing data\]. Baseline was the DSQ score of the 14-day period before randomization.
Time frame: Baseline, Week 16
Percent of Participants Who Were Overall Responders at The Final Treatment Period Evaluation
Overall response was defined as a reduction in the 2-week DSQ score of \>/= 30% and \>/= 50% from baseline to the final treatment period evaluation and a peak eosinophil count of \</= 6/high power field (light microscopy) (HPF) across all available esophageal levels at the final treatment period evaluation. An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value. Histopathology data were collected in a blinded fashion.
Time frame: Week 16
Change From Baseline in The Histopathologic Epithelial Features Combined Total Score at The Final Treatment Period Evaluation
Each esophageal biopsy specimen was evaluated microscopically by an independent, central pathologist for signs of epithelial inflammation and lamina propria fibrosis. Histopathologic epithelial features of each available esophageal level biopsy consisting of basal layer hyperplasia, eosinophil peak, dilated intercellular spaces, eosinophil microabcesses, surface layering, surface alteration, and apoptotic epithelial cells were scored and summed. Histopathology data were collected in a blinded fashion. Histopathology epithelial features were scored for both grade and stage. Each feature had a possible score of 0-3 for grade as well as stage. Thus each of the 3 levels had a possible score of 21, and a possible total grade or stage score of 63 for a maximum combined score of 126. The grade and stage score of the lamina propria was not included because the biopsy material was not available. A negative change from baseline indicates that epithelial inflammation decreased.
Time frame: Baseline, Week 16
Change From Baseline in The Total Endoscopy Score at The Final Treatment Period Evaluation
The gross endoscopic appearance of the esophageal surface was evaluated by a blinded study center physician. Endoscopic findings with separate evaluations of the proximal and distal esophagus were recorded with respect to 5 major categories, including exudates or plaques, fixed esophageal rings, edema, furrows, and strictures. The endoscopy score was the sum of the scores for the 5 major categories - grade 0-1 for strictures; grade 0-2 for exudates or plaques, edema, and furrows; and grade 0-3 for fixed esophageal rings for the proximal and distal locations. The maximum endoscopy score was 10 points for each location (proximal and distal), and the total endoscopy score was the sum of the scores for the proximal and distal locations (maximum total score of 20 points). Baseline was defined as the endoscopy score at screening. A negative change from baseline indicates that appearance improved.
Time frame: Baseline, Week 16
Change From Baseline in The Peak Eosinophil Count at Each Available Esophageal Level at The Final Treatment Period Evaluation
An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value across all available esophagus levels. Histopathology data were collected in a blinded fashion. Baseline was defined as the score at screening. A negative change from baseline indicates that eosinophil count decreased.
Time frame: Baseline, Week 16
Change From Baseline in The Physician's Global Assessment (PGA) of Disease Activity at The Final Treatment Period Evaluation
The physician Investigator (or qualified physician's assistant or nurse practitioner) completed the PGA to provide the global assessment of eosinophilic esophagitis (EoE) disease activity using a 0 to 100 mm visual analog scale (VAS) scale. The VAS is a 100 mm horizontal line on which the right extreme (100) is labeled "worst possible disease activity" and the left extreme (0) is labeled "no disease activity". The PGA raters were instructed to consider the line for the VAS a continuum with their own medical opinion or judgment of extremes on either end and to draw a vertical line at a point that best approximates the participant's current level of EoE disease activity. A negative change from baseline indicates that disease activity decreased.
Time frame: Baseline, Week 16
Distribution of Responses For The Patient Global Impression of Change (PGIC) Survey at The Final Treatment Evaluation
Participants evaluated the change in their dysphasia (food passing slowly/difficulty swallowing) since the start of the study (screening) by choosing 1 of 7 responses on the PGIC survey: much worse (-3), worse (-2), a little worse (-1), no change (0), a little better (1), better (2), or much better (3). The values reported are the percent of participants who chose that response.
Time frame: Week 16
Percent of Participants With Improved Symptoms on The Eosinophilic Esophagitis (EoE) Symptom Survey at The Final Treatment Period Evaluation
The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: Improved - participant reported a specific symptom at baseline, but changed to no specific symptom ('Yes' to 'No'); No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report a specific symptom at baseline, but changed to report that specific symptom ('No' to 'Yes').
Time frame: Week 16
Percent of Participants With No Change in Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation
The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: Improved - participant reported a specific symptom at baseline, but changed to no specific symptom ('Yes' to 'No'); No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report a specific symptom at baseline, but changed to report that specific symptom ('No' to 'Yes').
Time frame: Week 16
Percent of Participants With Worsened Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation
The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: Improved - participant reported a specific symptom at baseline, but changed to no specific symptom ('Yes' to 'No'); No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report a specific symptom at baseline, but changed to report that specific symptom ('No' to 'Yes').
Time frame: Week 16
Percent of Participants Without Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation
This outcome assessed the symptoms of participants who were symptom-free at baseline. The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: No change - participant did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report any symptom at baseline, but changed to report at least 1 symptom at the final treatment evaluation.
Time frame: Week 16
Percent of Participants With New Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation
This outcome assessed the symptoms of participants who were symptom-free at baseline. The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report any symptom at baseline, but changed to report at least 1 symptom at the final treatment evaluation.
Time frame: Week 16
Percent of Participants Who Were Symptom Responders on The DSQ+Pain Scale at The Final Treatment Period Evaluation
Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Question 1 (did you eat solid food) and Question 2 (did food pass slowly or get stuck). If the answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Question 3 (did you have to do anything to make the food go down or get relief) and Question 4 (extent to which the participant experienced pain while swallowing).The DSQ+pain response was defined as a \>/= 30% and \>/= 50% reduction from baseline in the combined score from Questions 2, 3, and 4. The 2-week DSQ+pain score was calculated by adding points from Questions 2, 3, and 4 and then taking the average of the available scores over each 2-week interval.
Time frame: Week 16
Percent of Days That Participants Reported That They Avoided Solid Food During The Baseline And Treatment Periods
Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). Values were calculated for all the days that Question 1 was answered from 14 days prior to baseline visit up to the final treatment period evaluation.
Time frame: From 14 days prior to the baseline visit to the final treatment period evaluation
Change From Baseline in The Scores of DSQ Question 1 During The Treatment Period
Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). Question 1 is rated as Yes (score=0) or No (score=1); higher values indicate a worse outcome. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.
Time frame: Baseline, Weeks 8, 12, and 16
Change From Baseline in The Scores of DSQ Question 4 During The Treatment Period
Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). Question 4 is rated as None, I had no pain (score=0), mild pain (score=1), moderate pain (score=2), severe pain (score=3), or very severe pain (score=4); 4 is the worst pain. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.
Time frame: Baseline, Weeks 8, 12, and 16
| Milestone | Single-blind Placebo | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg | Placebo to Open-label Oral Budesonide Suspension (OBS) 2 mg | Oral Budesonide Suspension (OBS) 2 mg to Open-label OBS 2 mg |
|---|---|---|---|---|---|
| Started | 119 | 0 | 0 | 0 | 0 |
| Completed | 93 | 0 | 0 | 0 | 0 |
| Not completed | 26 | 0 | 0 | 0 | 0 |
| Withdrew: Did not meet eligibility criteria | 26 | 0 | 0 | 0 | 0 |
| Milestone | Single-blind Placebo | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg | Placebo to Open-label Oral Budesonide Suspension (OBS) 2 mg | Oral Budesonide Suspension (OBS) 2 mg to Open-label OBS 2 mg |
|---|---|---|---|---|---|
| Started | 0 | 42 | 51 | 0 | 0 |
| Completed | 0 | 39 | 49 | 0 | 0 |
| Not completed | 0 | 3 | 2 | 0 | 0 |
| Withdrew: Other | 0 | 2 | 1 | 0 | 0 |
| Withdrew: Non-compliance | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 |
| Milestone | Single-blind Placebo | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg | Placebo to Open-label Oral Budesonide Suspension (OBS) 2 mg | Oral Budesonide Suspension (OBS) 2 mg to Open-label OBS 2 mg |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 37 | 45 |
| Completed | 0 | 0 | 0 | 27 | 37 |
| Not completed | 0 | 0 | 0 | 10 | 8 |
| Withdrew: Adverse event | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 7 | 4 |
| Withdrew: Consent withdrawn | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 |
Histologic response was defined as a peak eosinophil count \</= 6/high power field (light microscopy) (HPF) across all esophageal levels at the final treatment evaluation (Week 16). An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value. Histopathology data were collected in a blinded fashion.
| percent of participants | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Percent of Participants Who Were Histologic Responders | 2.6 | 38.8 |
Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing).The DSQ score was calculated based on responses to Questions 2 and 3 \[14 x (sum of points from Questions 2 and 3 in the daily DSQ)/number of diaries with non-missing data\]. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.
| scores on a scale | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Change From Baseline in The Dysphagia Symptom Questionnaire (DSQ) Score at The Final Treatment Period Evaluation | -7.53 ± 1.910 | -14.27 ± 1.682 |
Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing).The DSQ score was calculated based on responses to Questions 2 and 3 \[14 x (sum of points from Questions 2 and 3 in the daily DSQ)/number of diaries with non-missing data\]. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.
| scores on a scale | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Week 8, n = 37, 49 | -4.92 ± 1.673 | -7.41 ± 1.453 |
| Week 12, n = 36, 49 | -7.42 ± 2.065 | -10.33 ± 1.770 |
A cumulative distribution function curve was constructed to illustrate the cumulative proportion of participants (x-axis) vs. the change in the DSQ score from baseline to the final treatment evaluation (y-axis). The 50th percentile is participants with a DSQ score that is in the middle of the distribution of all scores. A negative change from baseline indicates that symptoms decreased.
| scores on a scale | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Change From Baseline in The DSQ Score For The 50th Percentile of Participants at The Final Treatment Period Evaluation | -6.35 | -11.20 |
An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value across all available esophagus levels. Histopathology data were collected in a blinded fashion. The values reported are for participants with histologic response.
| percent of participants | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| </= 15 Eosinophils/HPF | 7.9 | 46.9 |
| </= 1 Eosinophils/HPF | 0 | 30.6 |
Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing).The DSQ score was calculated based on responses to Questions 2 and 3 \[14 x (sum of points from Questions 2 and 3 in the daily DSQ)/number of diaries with non-missing data\]. Baseline was the DSQ score of the 14-day period before randomization.
| percent of participants | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| >/= 30% DSQ Score Reduction | 44.7 | 69.4 |
| >/= 50% DSQ Score Reduction | 39.5 | 63.3 |
Overall response was defined as a reduction in the 2-week DSQ score of \>/= 30% and \>/= 50% from baseline to the final treatment period evaluation and a peak eosinophil count of \</= 6/high power field (light microscopy) (HPF) across all available esophageal levels at the final treatment period evaluation. An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value. Histopathology data were collected in a blinded fashion.
| percent of participants | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Responder and >/= 30% DSQ Score Reduction | 2.6 | 26.5 |
| Responder and >/= 50% DSQ Score Reduction | 2.6 | 20.4 |
Each esophageal biopsy specimen was evaluated microscopically by an independent, central pathologist for signs of epithelial inflammation and lamina propria fibrosis. Histopathologic epithelial features of each available esophageal level biopsy consisting of basal layer hyperplasia, eosinophil peak, dilated intercellular spaces, eosinophil microabcesses, surface layering, surface alteration, and apoptotic epithelial cells were scored and summed. Histopathology data were collected in a blinded fashion. Histopathology epithelial features were scored for both grade and stage. Each feature had a possible score of 0-3 for grade as well as stage. Thus each of the 3 levels had a possible score of 21, and a possible total grade or stage score of 63 for a maximum combined score of 126. The grade and stage score of the lamina propria was not included because the biopsy material was not available. A negative change from baseline indicates that epithelial inflammation decreased.
| scores on a scale | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Change From Baseline in The Histopathologic Epithelial Features Combined Total Score at The Final Treatment Period Evaluation | -1.41 ± 2.970 | -23.75 ± 2.602 |
The gross endoscopic appearance of the esophageal surface was evaluated by a blinded study center physician. Endoscopic findings with separate evaluations of the proximal and distal esophagus were recorded with respect to 5 major categories, including exudates or plaques, fixed esophageal rings, edema, furrows, and strictures. The endoscopy score was the sum of the scores for the 5 major categories - grade 0-1 for strictures; grade 0-2 for exudates or plaques, edema, and furrows; and grade 0-3 for fixed esophageal rings for the proximal and distal locations. The maximum endoscopy score was 10 points for each location (proximal and distal), and the total endoscopy score was the sum of the scores for the proximal and distal locations (maximum total score of 20 points). Baseline was defined as the endoscopy score at screening. A negative change from baseline indicates that appearance improved.
| scores on a scale | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Change From Baseline in The Total Endoscopy Score at The Final Treatment Period Evaluation | 0.19 ± 0.530 | -3.58 ± 0.466 |
An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value across all available esophagus levels. Histopathology data were collected in a blinded fashion. Baseline was defined as the score at screening. A negative change from baseline indicates that eosinophil count decreased.
| eosinophils/HPF | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Proximal, n = 32, 45 | -30.06 ± 6.798 | -65.56 ± 5.704 |
| Mid-, n = 36, 46 | -17.34 ± 9.244 | -76.90 ± 8.173 |
| Distal, n = 38, 49 | -1.90 ± 9.852 | -69.28 ± 8.667 |
The physician Investigator (or qualified physician's assistant or nurse practitioner) completed the PGA to provide the global assessment of eosinophilic esophagitis (EoE) disease activity using a 0 to 100 mm visual analog scale (VAS) scale. The VAS is a 100 mm horizontal line on which the right extreme (100) is labeled "worst possible disease activity" and the left extreme (0) is labeled "no disease activity". The PGA raters were instructed to consider the line for the VAS a continuum with their own medical opinion or judgment of extremes on either end and to draw a vertical line at a point that best approximates the participant's current level of EoE disease activity. A negative change from baseline indicates that disease activity decreased.
| scores on a scale | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Change From Baseline in The Physician's Global Assessment (PGA) of Disease Activity at The Final Treatment Period Evaluation | -10.16 ± 4.199 | -28.61 ± 3.695 |
Participants evaluated the change in their dysphasia (food passing slowly/difficulty swallowing) since the start of the study (screening) by choosing 1 of 7 responses on the PGIC survey: much worse (-3), worse (-2), a little worse (-1), no change (0), a little better (1), better (2), or much better (3). The values reported are the percent of participants who chose that response.
| percent of participants | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Much Worse | 0 | 0 |
| Worse | 2.6 | 2.1 |
| A Little Worse | 13.2 | 2.1 |
| No Change | 15.8 | 12.5 |
| A Little Better | 28.9 | 25.0 |
| Better | 28.9 | 25.0 |
| Much Better | 10.5 | 33.3 |
The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: Improved - participant reported a specific symptom at baseline, but changed to no specific symptom ('Yes' to 'No'); No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report a specific symptom at baseline, but changed to report that specific symptom ('No' to 'Yes').
| percent of participants | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Heartburn | 10.5 | 18.4 |
| Chest Pain | 23.7 | 18.4 |
| Regurgitation | 15.8 | 20.4 |
| Abdominal Pain | 15.8 | 10.2 |
| Nausea | 10.5 | 16.3 |
| Vomiting | 5.3 | 4.1 |
The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: Improved - participant reported a specific symptom at baseline, but changed to no specific symptom ('Yes' to 'No'); No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report a specific symptom at baseline, but changed to report that specific symptom ('No' to 'Yes').
| percent of participants | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Heartburn | 86.8 | 71.4 |
| Chest Pain | 68.4 | 71.4 |
| Regurgitation | 71.1 | 73.5 |
| Abdominal Pain | 76.3 | 85.7 |
| Nausea | 86.8 | 77.6 |
| Vomiting | 81.6 | 91.8 |
The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: Improved - participant reported a specific symptom at baseline, but changed to no specific symptom ('Yes' to 'No'); No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report a specific symptom at baseline, but changed to report that specific symptom ('No' to 'Yes').
| percent of participants | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Heartburn | 2.6 | 10.2 |
| Chest Pain | 7.9 | 10.2 |
| Regurgitation | 13.2 | 6.1 |
| Abdominal Pain | 7.9 | 4.1 |
| Nausea | 2.6 | 6.1 |
| Vomiting | 13.2 | 4.1 |
This outcome assessed the symptoms of participants who were symptom-free at baseline. The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: No change - participant did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report any symptom at baseline, but changed to report at least 1 symptom at the final treatment evaluation.
| percent of participants | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Percent of Participants Without Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation | 71.1 | 83.7 |
This outcome assessed the symptoms of participants who were symptom-free at baseline. The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report any symptom at baseline, but changed to report at least 1 symptom at the final treatment evaluation.
| percent of participants | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Percent of Participants With New Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation | 28.9 | 16.3 |
Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Question 1 (did you eat solid food) and Question 2 (did food pass slowly or get stuck). If the answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Question 3 (did you have to do anything to make the food go down or get relief) and Question 4 (extent to which the participant experienced pain while swallowing).The DSQ+pain response was defined as a \>/= 30% and \>/= 50% reduction from baseline in the combined score from Questions 2, 3, and 4. The 2-week DSQ+pain score was calculated by adding points from Questions 2, 3, and 4 and then taking the average of the available scores over each 2-week interval.
| percent of participants | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| >/= 30% DSQ+pain Score Reduction | 47.4 | 67.3 |
| >/= 50% DSQ+pain Score Reduction | 39.5 | 65.3 |
Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). Values were calculated for all the days that Question 1 was answered from 14 days prior to baseline visit up to the final treatment period evaluation.
| percentage of days | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Percent of Days That Participants Reported That They Avoided Solid Food During The Baseline And Treatment Periods | 1.2 (0.0 to 1.1) | 0.7 (0.0 to 1.2) |
Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). Question 1 is rated as Yes (score=0) or No (score=1); higher values indicate a worse outcome. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.
| scores on a scale | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Week 8, n = 37, 49 | 0.02 ± 0.050 | -0.08 ± 0.043 |
| Week 12, n = 36, 49 | 0.05 ± 0.091 | 0.02 ± 0.078 |
| Week 16, n = 38, 49 | 0.05 ± 0.079 | 0.06 ± 0.069 |
Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). Question 4 is rated as None, I had no pain (score=0), mild pain (score=1), moderate pain (score=2), severe pain (score=3), or very severe pain (score=4); 4 is the worst pain. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.
| scores on a scale | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg |
|---|---|---|
| Week 8, n = 37, 47 | -2.52 ± 0.778 | -3.25 ± 0.690 |
| Week 12, n = 36, 47 | -2.97 ± 0.775 | -4.89 ± 0.678 |
| Week 16, n = 38, 47 | -3.08 ± 0.824 | -4.87 ± 0.741 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Placebo | — | 0/42 (0%) | 21/42 (50%) |
| Double-blind Oral Budesonide Suspension (OBS) 2 mg | — | 1/51 (2%) | 20/51 (39.2%) |
| Placebo to Open-label Oral Budesonide Suspension (OBS) 2 mg | — | 1/37 (2.7%) | 29/37 (78.4%) |
| Oral Budesonide Suspension (OBS) 2 mg to Open-label OBS 2 mg | — | 0/45 (0%) | 27/45 (60%) |
| Event | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg | Placebo to Open-label Oral Budesonide Suspension (OBS) 2 mg | Oral Budesonide Suspension (OBS) 2 mg to Open-label OBS 2 mg |
|---|---|---|---|---|
| Hand FractureInjury, poisoning and procedural complications | 0/42 | 0/51 | 1/37 | 0/45 |
| Road Traffic AccidentInjury, poisoning and procedural complications | 0/42 | 0/51 | 1/37 | 0/45 |
| Food poisoningGastrointestinal disorders | 0/42 | 1/51 | 0/37 | 0/45 |
| Event | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg | Placebo to Open-label Oral Budesonide Suspension (OBS) 2 mg | Oral Budesonide Suspension (OBS) 2 mg to Open-label OBS 2 mg |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/42 | 3/51 | 4/37 | 5/45 |
| Oesophageal candidiasisInfections and infestations | 0/42 | 1/51 | 4/37 | 0/45 |
| Upper respiratory tract infectionInfections and infestations | 2/42 | 3/51 | 4/37 | 3/45 |
| Wrist fractureInjury, poisoning and procedural complications | 0/42 | 0/51 | 3/37 | 0/45 |
| HeadacheNervous system disorders | 0/42 | 1/51 | 3/37 | 1/45 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/42 | 0/51 | 3/37 | 0/45 |
| Vulvovaginal mycotic infectionInfections and infestations | 1/42 | 0/51 | 2/37 | 0/45 |
| AcneSkin and subcutaneous tissue disorders | 0/42 | 1/51 | 2/37 | 0/45 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/42 | 2/51 | 0/37 | 1/45 |
| DiarrhoeaGastrointestinal disorders | 1/42 | 1/51 | 0/37 | 2/45 |
The Safety Analysis Set, defined as all randomized participants who received at least 1 dose of double-blind study drug (placebo or OBS); subjects were analyzed based on the actual treatment received.
| Age, Continuous(years) | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg | Total |
|---|---|---|---|
| Mean | 20.8 ± 7.50 | 22.3 ± 7.92 | 21.6 ± 7.73 |
| Age, Customized(Participants) | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg | Total |
|---|---|---|---|
| <18 Years Of Age | 17 | 18 | 35 |
| >/= 18 Years Of Age | 25 | 33 | 58 |
| Sex: Female, Male(Participants) | Double-blind Placebo | Double-blind Oral Budesonide Suspension (OBS) 2 mg | Total |
|---|---|---|---|
| Female | 13 | 16 | 29 |
| Male | 29 | 35 | 64 |
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2012 to primary completion in Oct 2014, 27 months.
Results were first posted in Dec 2015, 1 year 1 month after primary completion.
Of 24 phase 2 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 27 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide